A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?

被引:12
作者
Cross, J. Helen [1 ,2 ,3 ]
Cock, Hannah [4 ,5 ]
机构
[1] UCL NIHR BRC Great Ormond St Inst Child Hlth, Guilford St, London WC1N 1EH, England
[2] Great Ormond St Children NHS Trust, Great Ormond St, London WC1N 3JH, England
[3] Young Epilepsy, Surrey, England
[4] St Georges Univ London, Inst Mol & Clin Sci, London SW17 0RE, England
[5] St Georges Univ Hosp NHS Fdn Trust, Atkinson Morley Reg Epilepsy Network, Blackshaw Rd, London SW17 0QT, England
基金
英国工程与自然科学研究理事会;
关键词
Cannabidiol; Epilepsy; Dravet syndrome; Lennox Gastaut syndrome; Cannabis based medicinal products; TREATMENT-RESISTANT EPILEPSY; ANTIEPILEPTIC DRUGS; CANNABIDIOL; SEIZURES; TRIAL; ACCURACY; EXTRACTS; RECEPTOR; HISTORY;
D O I
10.1016/j.neuropharm.2019.107861
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
With the licensing of cannabidiol for drug resistant seizures in Dravet and Lennox Gastaut syndromes in the United states in 2018, interest in the potential for cannabis-based-medicinal products to meet currently unmet needs for people with epilepsy continues to grow. This review summarizes current knowledge and discusses the implications for future research and practice. Both cannabidiol and tetrahydrocannabinol, the main components, have been extensively studied in animal models, with multimodal mechanisms of action proposed. Only pure cannabidiol formulations have been rigorously evaluated in controlled trials thus far, with modest but significant improvements in motor seizures. Adverse effects include diarrhoea, somnolence and reduced appetite, with mostly acceptable tolerability, but a not insignificant (up to 1 in 23) risk of serious adverse events. Recognized drug interactions include with valproate (increased risk of hepatotoxicity) and clobazam (contributing to somnolence, increased secretions, probably chest infections, and potentially efficacy). Whilst there is public (and producer) interest in products also containing tetrahydrocannabinol, clinicians have justifiable concerns about exposing a group already vulnerable to mental health and neurobehavioural comorbidities to the associated additional risks in these domains. Artisanal preparations, with often inconsistent/unknown constituents are frequently used but not recommended. A gulf exists between the actual evidence, including a lack of comparative studies and public beliefs, fuelled by media and anecdote. Continued education of the public, policymakers, researchers and healthcare providers about what is and isn't yet known, together with on-going good quality research is essential to mitigate against future potential risks, particularly in relation to vulnerable populations. This article is part of the special issue entitled 'New Epilepsy Therapies for the 21st Century - From Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy'.
引用
收藏
页数:7
相关论文
共 60 条
  • [1] Barnes M.P., 2018, BMJ-BRIT MED J, V362, P138
  • [2] Bazelot M, 2018, EPILEPSIA, V59, pS252
  • [3] Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development
    Bialer, Meir
    Johannessen, Svein I.
    Koepp, Matthias J.
    Levy, Rene H.
    Perucca, Emilio
    Tomson, Torbjorn
    White, H. Steve
    [J]. EPILEPSIA, 2018, 59 (10) : 1842 - 1866
  • [4] Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy
    Birnbaum, Angela K.
    Karanam, Ashwin
    Marino, Susan E.
    Barkley, Christopher M.
    Remmel, Rory P.
    Roslawski, Michaela
    Gramling-Aden, Mary
    Leppik, Ilo E.
    [J]. EPILEPSIA, 2019, 60 (08) : 1586 - 1592
  • [5] Labeling Accuracy of Cannabidiol Extracts Sold Online
    Bonn-Miller, Marcel O.
    Loflin, Mallory J. E.
    Thomas, Brian F.
    Marcu, Jahan P.
    Hyke, Travis
    Vandrey, Ryan
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (17): : 1708 - 1709
  • [6] Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison
    Bootsma, H. P. R.
    Ricker, L.
    Diepman, L.
    Gehring, J.
    Hulsman, J.
    Lambrechts, D.
    Leenen, L.
    Majoie, M.
    Schellekens, A.
    de Krom, M.
    Aldenkamp, A. P.
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2008, 17 (01): : 19 - 26
  • [7] Polypharmacology Shakes Hands with Complex Aetiopathology
    Brodie, James S.
    Di Marzo, Vincenzo
    Guy, Geoffrey W.
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (12) : 802 - 821
  • [8] Cannabinoid Delivery Systems for Pain and Inflammation Treatment
    Bruni, Natascia
    Della Pepa, Carlo
    Oliaro-Bosso, Simonetta
    Pessione, Enrica
    Gastaldi, Daniela
    Dosio, Franco
    [J]. MOLECULES, 2018, 23 (10):
  • [9] An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use
    Budney, Alan J.
    Sofis, Michael J.
    Borodovsky, Jacob T.
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2019, 269 (01) : 73 - 86
  • [10] Buracchio T., 2018, USE CANNABIDIOL TREA